DeepMed Research

Ferring Pharmaceuticals, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ferringusa.com

Clinical Trials

Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women

Phase 3

Completed

Conditions: Controlled Ovarian Simulation

Interventions: Drug: Follitropin delta
Drug: Follitropin alfa

First Posted Date: 2017-09-28

Last Posted Date: 2023-08-24

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 1011

Registration Number: NCT03296527

Locations: 🇨🇳
Beijing Obstetrics and Gynecology Hospital,Capital Medical University, Beijing, China
🇨🇳
ShengJing Hospital of China Medical University, Shenyang, China
🇨🇳
The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

and more 23 locations

Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome

Terminated

Conditions: Growth Disorders

Interventions: Drug: Zomacton

First Posted Date: 2017-09-07

Last Posted Date: 2018-12-13

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 4

Registration Number: NCT03274973

Locations: 🇩🇪
Klinik fuer Allgemeine Paediatrie der Christian-Albrechts-Universitaet zu Kiel (there might be other sites in this country), Kiel, Germany

Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women

Phase 3

Completed

Conditions: Infertility

Interventions: Drug: Follitropin delta
Drug: Follitropin beta

First Posted Date: 2017-07-25

Last Posted Date: 2023-08-24

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 373

Registration Number: NCT03228680

Locations: 🇯🇵
Investigational Site 8121, Chiba-shi, Chiba, Japan
🇯🇵
Yachiyo Hospital, Anjo, Aichi, Japan
🇯🇵
Saint Women's Clinic, Saitama, Japan

and more 14 locations

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

Phase 2

Completed

Conditions: Nocturia

Interventions: Drug: FE 201836
Drug: Desmopressin
Drug: Placebo oral solution
Drug: Placebo ODT

First Posted Date: 2017-06-28

Last Posted Date: 2022-03-02

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 302

Registration Number: NCT03201419

Locations: 🇺🇸
Advanced Rx Clinical Research Group, Inc., Westminster, California, United States
🇺🇸
MCA Research - Partner, Houston, Texas, United States
🇺🇸
Doctors Research Institute Corporation, Miami, Florida, United States

and more 68 locations

Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2017-06-21

Last Posted Date: 2019-02-26

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 150

Registration Number: NCT03193645

Locations: 🇫🇷
Hopital de la Source (there may be multiple sites in this country), Orléans, France

Study of Minirin Melt® in Adult Patients With Nocturia

Terminated

Conditions: Nocturia

First Posted Date: 2017-03-24

Last Posted Date: 2021-02-05

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 835

Registration Number: NCT03089073

Locations: 🇰🇷
Daegu Fatima Hospital (there may be other sites in this country), Daegu, Korea, Republic of

An Open-label Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term

Phase 3

Completed

Conditions: Cervical Ripening

Interventions: Drug: Dinoprostone

First Posted Date: 2017-03-01

Last Posted Date: 2021-04-09

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 68

Registration Number: NCT03067597

Locations: 🇯🇵
Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan
🇯🇵
Hamamatsu University Hospital, Hamamatsu, Shizuoka, Japan
🇯🇵
Itabashi Chuo Medical Center, Itabashi, Tokyo, Japan

and more 11 locations

A Randomised Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term

Phase 3

Completed

Conditions: Cervical Ripening

Interventions: Drug: Placebo
Drug: Dinoprostone

First Posted Date: 2017-03-01

Last Posted Date: 2020-11-03

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 114

Registration Number: NCT03067727

Locations: 🇯🇵
Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan
🇯🇵
Itabashi Chuo Medical Center, Itabashi, Tokyo, Japan
🇯🇵
University of Tsukuba Hospital, Ibaraki, Japan

and more 17 locations

Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

Phase 3

Completed

Conditions: Nocturia

Interventions: Drug: Desmopressin ODT 25 μg
Drug: Desmopressin ODT 50 μg

First Posted Date: 2017-02-13

Last Posted Date: 2018-09-17

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 503

Registration Number: NCT03051009

Locations: 🇯🇵
Investigational site (there may be other sites in this country), Tokyo, Japan

AMPLEX Ankle Fusion and Hindfoot

Not Applicable

Completed

Conditions: Arthrodesis Surgery Involving the Hindfoot or Ankle

Interventions: Device: AMPLEX
Procedure: Autogenous Bone Graft (ABG)

First Posted Date: 2017-01-23

Last Posted Date: 2021-03-11

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT03028415

Locations: 🇺🇸
Michigan Orthopedic Center, Lansing, Michigan, United States
🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇺🇸
Baylor St. Luke's Medical Center, Houston, Texas, United States

and more 33 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy